Boston Scientific announces schedule of presentations at TCT 2019

Boston Scientific has announced the key data that will be presented at the Transcatheter Cardiovascular Therapeutics […]

Boston Scientific has announced the key data that will be presented at the Transcatheter Cardiovascular Therapeutics conference (TCT 2019; 25–29 September, San Francisco, USA).
Data from the EVOLVE Short DAPT study, evaluating the safety of early dual antiplatelet therapy discontinuation in a large number of patients with high bleeding risk treated with the SYNERGY™ bioabsorbable polymer (BP) stent, will be featured during a late-breaking science session on Thursday 26 September.
“We look forward to the presentation of late-breaking data on our SYNERGY stent and the important discussions these data will warrant around the advancement of therapies to treat coronary artery disease,” said Ian Meredith, executive vice president and global chief medical officer at Boston Scientific. “We also will celebrate the milestone of 100,000 patient implants of the WATCHMAN left atrial appendage closure device worldwide, and anticipate new clinical data across our Interventional cardiology portfolio, further supporting physicians as they determine the most appropriate treatment strategies for patients with cardiovascular disease.”
Other abstracts of interest highlighted by the company include:

  • LOTUS aortic valve system: Mid-term outcomes after transcatheter aortic valve replacement with a mechanically-expanded versus self-expandable valve: three-year results from the REPRISE III randomised Trial, presented by David Rizik
  • SYNERGY BP stent (late-breaking): Primary outcomes of the EVOLVE short DAPT Study evaluating three-Month dual antiplatelet therapy in high lleeding risk patients treated With the SYNERGY everolimus-eluting, bioabsorbable polymer-coated coronary stent
  • LOTUS aortic valve system: Budget impact of mechanically expanded versus self-expanding transcatheter aortic valve replacement in high-risk patients with aortic stenosis: A Medicare perspective
  • PLATINUM Diversity: Clinical impact of DAPT cessation within 12 months of drug-eluting stent implantation in caucasians and minorities: Insights from the PLATINUM Diversity and PROMUS Element Plus post-approval
  • WATCHMAN left atrial appendage closure device: Budget implications of atrial fibrillation stroke risk reduction strategies to Medicare and Medicare beneficiaries: An analysis of pooled, long-term trial data
  • PLATINUM Diversity: Clinical outcomes in women and minorities according to the urgency of percutaneous coronary intervention.

The company will also host an investor event and webcast on Friday 27 September.
Original Article: (